louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02316769: Comparison Study of the McGrath MAC Video Laryngoscope With the King Vision
Official title: Randomized Controlled Trial Comparing the McGrath MAC Video Laryngoscope With the King Vision Video Laryngoscope in Adult Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Video Laryngoscopic Device Usage in Novice Users
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2014-12-15
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, the investigators compare the effectiveness of two relatively new video laryngoscopes, McGrath MAC (Covidien, Dublin Ireland) and the King Vision (King Systems, Noblesville, IN), by practitioners experienced in airway management but with limited exposure to these two devices. Our hypothesis was that, the McGrath MAC device would require fewer intubation attempts and shorter intubation times than the King Vision when performed by novice users.


Eligibility criteria: Inclusion Criteria:

* All interested airway providers (Residents, Attendings, Certified Nurse Anesthetist and
* Student Registered Nurse Anesthetist) will be eligible to be included. -

Exclusion Criteria:

* All patients with difficult airways as determined by history or physical exam (limited oral opening, limited cervical extension, receding chin, Mallampati class III or IV).

Primary outcomes:
measure: Intubation Success on First Attempt as Measured by End Tidal Carbon Dioxide
timeFrame: participants were followed up to the point the video device is removed from the airway, classified as under 90 seconds.
Secondary outcomes:
measure: Time to Intubation
timeFrame: Intubation time was initiated at the time of entry of the study device beyond the teeth/gum line and the intubation time was stopped when the study device was removed beyond the same point.
Other outcomes:
Locations:
Study officials:
affiliation: Vanderbilt University
name: Bret Alvis
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01051869: Simple Decompression Versus Anterior Transposition of the Ulnar Nerve
Official title: A Multicentre, Randomized Trial of Simple Decompression Versus Anterior Transposition of the Ulnar Nerve for Acute, Displaced Fractures of the Distal Humerus Treated With Plate Fixation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Humeral Fractures
Ulnar Nerve Compression
Keywords: distal humerus
fractures
ulnar nerve
simple decompression
anterior transposition
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2010-01-20
Enrollment: 56
Sex: ALL
Minimum age (years): 16
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Both simple decompression and anterior transposition of the elbow nerve (ulnar nerve) for acute displaced fractures of the elbow (distal humerus) treated with plate fixation are currently used by surgeons. We want to examine which treatment will overall give better results in regards to arm function and residual pain.


Eligibility criteria: Inclusion Criteria:

* Men or women aged 16 to 60 years of age
* Displaced, distal humerus fracture (OTA 13A or 13C) as seen in radiographs
* Fractures ≤ 28 days post injury
* Closed fractures
* No history of previous ulnar neuropathy or elbow pathology
* Provisin of informed consent

Exclusion Criteria:

* Vascular injury
* History of previous ulnar neuropathy or elbow pathology
* Fractures more than 28 days post-injury
* Limited life expectancy due to significant medical co-morbidity or medical contraindication to surgery
* Inability to comply with rehabilitation or form completion
* Likely problems, in the judgement of the investigators, with maintaining follow-up (i.e. patients with no fixed address, patients not mentally competent to give consent, etc.)

Primary outcomes:
measure: The primary outcome will be signs of ulnar neuropathy, measured using two clinical staging systems to assess the degree of dysfunction of the ulnar nerve (the classification system of Gabel and Amadio13).
timeFrame: 1 Year
Secondary outcomes:
measure: Secondary outcome measurement will include a patient-oriented, limb-specific, functional measurement questionnaire (Disabilities of the Arm, Shoulder and Hand Instrument-DASH)
timeFrame: 1 Year
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
Study officials:
affiliation: Unity Health Toronto
name: Emil H Schemitsch, MD, FRCS(C)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04479969: Enabling Independent Living by Expanding Access to Home-Based Pulmonary Rehabilitation
Official title: Enabling Independent Living by Expanding Access to Home-Based Pulmonary Rehabilitation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2020-07-21
Enrollment: 9
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to test an existing home-based pulmonary rehab program with the addition of video chat and a capability of a Spanish version.

Detailed description: The purpose of this research is to test video chat on a computer tablet that is used for Pulmonary Rehabilitation. We are interested in learning patients' thoughts on how easy or difficult video chat is to use and the translation to Spanish and the feed back from Spanish speaking patients .

Eligibility criteria: Inclusion Criteria:

* Patients must be ≥ 40 years old.
* Patients mist have a diagnosis of GOLD stage II, III, or IV COPD documented by pulmonary function testing.
* Patients must be a current or previous smoker with at least 10 pack-years of cigarette smoking.

Additional Inclusion Criteria to test Spanish version of system:

* Be a native Spanish speaker.

Exclusion Criteria:

* Patients with a high likelihood of being lost to follow-up or contact (patients with active chemical dependency).
* Patients planning to move out of the state or who are not living in the healthcare area.
* Patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).

Primary outcomes:
measure: Qualitative Interview
timeFrame: Week 1
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Roberto P Benzo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05662969: Machine Perfusion in High vs Low/Mid-volume Liver Transplant Centers: a Multicentre Survey
Official title: Machine-perfusion for Liver Transplantation in High Versus Low/Mid-volume Centres: an International Multicentre Survey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Organ Preservation Solution
Keywords: machine perfusion
liver transplant
low/mid volume transplant center
Lead sponsor: University of Rome Tor Vergata
Sponsor class: OTHER
First posted: 2022-12-23
Enrollment: 67
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 67 LT centres divided by a cutoff of 60LT/year in: 31 low/mid-volume LT centres (\<60LT/year) and 36 high-volume LT centres (\>60 LT/year)

Brief summary: Introduction: Machine perfusion (MP) was developed to expand the available donor pool and to improve liver transplantation outcomes. Despite optimal results in clinical trials, MP benefit outside of clinical experimentation in unknown. Low/mid volume centres (L/MVCs) may face logistical/economical difficulties that may in turn hamper optimal MP results.

Methods: An Online 22-item survey on the use of machine perfusion for liver transplantation outside of clinical trials, was distributed to worldwide LT centres representatives. Variables of interest included MP logistics, MP technicalities, MP results, post-MP LT results. Responding centres were grouped into high volume centre (HVCs)(defined as \>60 LTs per year in 2019) and L/MVCs. Results from HVCs vs L/MVCs were compared.


Eligibility criteria: Inclusion Criteria:

* LT centres that use MP
* LT centres which perform LT before pandemic time (before 2019 included)
* LT centres which perform LT from cadaveric donors and living donors

Exclusion Criteria:

* LT centres that not use MP
* LT centres that use MP but on clinical trials

Primary outcomes:
measure: Liver transplant(LT) centres different use of graft after utilization of machine perfusion (MP)
timeFrame: 12/2021 - 03/2022
Secondary outcomes:
measure: Liver Transplant outcomes after Machine Perfusion
timeFrame: 12/2021 - 03/2022
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Roberta Angelico
Study officials:
References:
Clinical trial NCT04082169: Causes and Consequences of Primary Ovarian Insufficiency
Official title: Causes and Consequences of Primary Ovarian Insufficiency
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Primary Ovarian Insufficiency
Premature Menopause
Lead sponsor: Haukeland University Hospital
Sponsor class: OTHER
First posted: 2019-09-09
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 100 women with primary ovarian insufficiency defined as absence of menstruation more than 4 months and serum level of follicle stimulation hormone (FSH) in menopausal range at 2 or more occations

Brief summary: 100 women with primary ovarian insufficiency will be included for extensive diagnostic workup to improve diagnostic precision by extended autoantibody screening and genetic and toxicological testing.


Eligibility criteria: Inclusion Criteria:Women 40 years or younger, more than 4 months amenorrhea, more than 2 FSH measurements in menopausal range (drawn at least 2 months apart), ability to provide informed concent -

Exclusion Criteria:History of oophorectomy, chemotherapy or radiation

-

Primary outcomes:
measure: Autoimmune
timeFrame: one day
measure: Genetic
timeFrame: one day
measure: Endocrine disrupting chemicals
timeFrame: one day
Secondary outcomes:
measure: Phenotype description
timeFrame: one day
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: HaukelandUH
Study officials:
affiliation: Haukeland University Hospital
name: Kahtan Al-Azawy, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00180869: Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients
Official title: A Randomized Study of Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion During Surgery in Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cancer
Surgery
Keywords: cancer
peroperative transfusion
allogeneic red blood cell concentrate
leuko-reduced red blood cell concentrate
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There is evidence to suggest that red blood cell concentrate (RBC) transfusion may have immunomodulatory effects. The aim of this randomized single-center trial is to compare immune responses in patients undergoing cancer surgery and given either an unmodified RBC (UN-RBC) or a leuko-reduced RBC (LR-RBC) transfusion perioperatively.

Detailed description: This single-center study is conducted to compare the effect of peroperative transfusion of allogeneic unmodified RBC (UN-RBC) versus leuko-reduced RBC (RED-RBC) on recipient immunity. Patients undergoing cancer surgery are randomly assigned peroperatively to receive UN-RBC or RED-RBC. Groups are stratified for age, sex, tumor characteristics, prior transfusion and prior cancer treatment. Blood sampless are collected before anesthesia (d0) and at days 3, 7, 14 , 28 after transfusion/surgery and analyzed for complete cell blood count, lymphocyte subsets, cytokine production (IL4, IL10, IFNgamma, IL12), T-cells repertoire (TCR) analysis and detection of circulating donor cells. Main study endpoint is the influence of the treatment arm on IL4/IFNgamma ratio. The effect of transfusion type on any given biological parameters is also tested (peripheral blood mononuclear cell phenotyping (PBMC), cytokine production by stimulated PBMC, T cell repertoire analysis and microchimerism assessment).

Eligibility criteria: Inclusion Criteria:

* Surgery for cancer with a transfusion during surgery risk greater than 30%
* Surgery in curative intent
* Written informed consent

Exclusion Criteria:

* contraindications to the use of allogeneic unmodified red blood cell concentrate
* any anti-RBC and/or anti-HLA and/or anti-granulocyte alloimmunization

Primary outcomes:
measure: Polarization of lymphocyte responses towards a Th2 response following transfusion during surgery as assessed by the IL-4/IFN-γ ratio
Secondary outcomes:
measure: Peripheral blood mononuclear cell phenotyping
measure: Cytokine production
measure: Microchimerism at day 3 after transfusion during surgery
measure: Alteration of T cell repertoire
measure: Incidence of nosocomial infection
measure: Survival
Other outcomes:
Locations:
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Valerie Lapierre, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06927869: Pully System Exercise Role in Management of Spasticity
Official title: Effect of Pully System Exercise in Management of Spasticity in Cerebral Palsy Children: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Cerebral Palsy
Keywords: pully system
cerebral palsy
spasticity
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2025-04-15
Enrollment: 40
Sex: ALL
Minimum age (years): 5
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to investigate the effect of pully system exercise in in management of spasticity in cerebral palsy children

Does pully system exercise has role in management of spasticity in cerebral palsy children ?

Participants will:

The participants assigned to the control group will receive a standard care program. This program is designed to provide basic supportive therapies without the specialized pulley system exercises

Detailed description: there are two groups one group will receive traditional physical therapy programme another group will receive pully system exercise

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria
* The degree of spasticity is (1) according to Modified Ashwarth's scale
* They able to understand orders given to them.
* All children evaluated before and after the suggested period of the physical therapy program (3months).

Exclusion Criteria:

* - No fixed deformities.
* They have neither visual nor auditory problems.
* They have neither perceptual nor cognitive problems.

Primary outcomes:
measure: gross motor function of children with cerebral palsy using GMFMS
timeFrame: 3 months
measure: pediatric balance scale
timeFrame: 3 months
Secondary outcomes:
measure: spasticity with EMG
timeFrame: 3 months
Other outcomes:
measure: erobic capacity
timeFrame: 3 months
Locations:
city: Tanta
country: Egypt
facility: Elsalam university
Study officials:
References:
Clinical trial NCT06374069: Longevity Families of the Netherlands
Official title: Longevity Families of the Netherlands
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Longevity
Familial Longevity
Extreme Longevity
Aging
Lead sponsor: Leiden University Medical Center
Sponsor class: OTHER
Collaborators: name: Jacobijn Gussekloo, Prof. dr.
name: Simon P. Mooijaart, Prof. dr.
First posted: 2024-04-18
Enrollment: 600
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: FAMILY_BASED
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Dutch Caucasian descent:

Ages 75 and older, with siblings enriched for familial longevity, and individuals without a history of familial longevity

Brief summary: The demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Families surviving into exceptionally high ages (longevity) in good physical and mental health illustrate that this is physiologically possible. Such families harbor cross generational socio-genetic mechanisms that mediate healthy aging and protection from (multi)morbidity.

The purpose of our research is: to identify gene variants associated with healthy aging and protection from (multi)morbidity; to study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component.


Eligibility criteria: Inclusion Criteria:

* Siblings of Dutch Caucasian descent age 75+ enriched for familial longevity
* Individuals of Dutch Caucasian descent age 75+ who are not enriched for familial longevity

Exclusion Criteria:

-

Primary outcomes:
measure: Identifying the genetic variants of Familial Longevity
timeFrame: through study completion, an average of 2 years
Secondary outcomes:
measure: Studying the environmental factor of Familial Longevity through questionnaires and its interaction with the genetic component
timeFrame: through study completion, an average of 2 years
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
state: South Holland
Study officials:
References:
Clinical trial NCT03685669: Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients
Official title: Detection of Early-stage Lung Cancer by Using Methylation Signatures in Circulating Tumor DNA
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Nodule
Keywords: DNA methylation
ctDNA
Lead sponsor: Shanghai Chest Hospital
Sponsor class: OTHER
Collaborators: name: Singlera Genomics Inc.
First posted: 2018-09-26
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients who have single or multiple lung nodules detected by LDCT and are about to undergo surgery; healthy sex and age matched controls

Brief summary: Low-dose computed tomography (LDCT) is recommended for early-stage lung cancer screening. However, it is often difficult to determine indolent lesions from more aggressive tumors without an invasive intervention or prolonged follow-up period. Thus, the main purpose of this study is to develop a non-invasive method to detect lung-cancer specific circulating tumor DNA (ctDNA) in blood, which can greatly improve the specificity of lung cancer early screening.

Detailed description: In this study, the investigators sought to explore sensitive and specific methylation biomarkers that are highly prevalent in lung cancer. It is the first time to perform screening assay on healthy, lung nodule, and lung cancer tissues to identify preliminary set of highly prevalent methylation markers, and then refined these markers by removing regions were unstable in matched plasma samples. Next, investigators interrogated significant methylation marker regions enriched in lung nodules of training sample set to buildup a non-invasive biomarker classification model to discriminate cancerous nodules from benign lesions. Eventually, the model in patient lung nodule samples were validated.

Eligibility criteria: Inclusion Criteria:

1. 18 years old or above with pulmonary nodule(s) found by LDCT, mean diameter below 30mm.
2. The nodule lesion is peripheral, no signs of lymphatic infiltration or distal metastasis.
3. Fit and consent to surgical resection.
4. Agree to participate in this study and sign informed consents.

Exclusion Criteria:

1. Fail to understand or agree to sign informed consent.
2. Patients who did not follow the test plan for timely blood collection or did not cooperate with the study follow-up work.
3. Patients with previous history of cancer and/or cancer treatment such as surgery, radiotherapy, chemotherapy or targeted therapy.
4. Failing to meet the requirements for blood sampling.

Primary outcomes:
measure: Noninvasive assisted diagnosis of benign and malignant pulmonary nodules
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Chest Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT03404869: Study of ORL-1M (D-mannose) in Patients With CDG-Ib
Official title: Study of ORL-1M (D-mannose) in Patients With CDG-Ib
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: CDG Ib
Keywords: CDGIb MANNOSEPHOSPHATE ISOMERASE DEFICIENCY MPI DEFICIENCY PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME SAGUENAY-LAC SAINT-JEAN SYNDROME SLSJ SYNDROME
Lead sponsor: Orpha Labs
Sponsor class: INDUSTRY
First posted: 2018-01-19
Enrollment: 5
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study of ORL-1M in Patients With CDG-Ib


Eligibility criteria: Inclusion Criteria:

* Diagnosis of CGD-1b.
* Less than 18 years old.

Exclusion Criteria:

* Diagnosis of any other disease that is not a manifestation of CGD-1b.

Primary outcomes:
measure: Improvement in hypoglycemia, diarrhea and vomiting.
timeFrame: 6 months after treatment started
Secondary outcomes:
measure: Improved glycosylation pattern of serum transferrin.
timeFrame: 30 days after treatment started
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Orpha Labs
Study officials:
References:
citation: Rebelo AL, Chevalier MT, Russo L, Pandit A. Role and therapeutic implications of protein glycosylation in neuroinflammation. Trends Mol Med. 2022 Apr;28(4):270-289. doi: 10.1016/j.molmed.2022.01.004. Epub 2022 Feb 1.